Literature DB >> 10348764

Species differences in the proportion of plasma lipoprotein lipid carried by high-density lipoproteins influence the distribution of free and liposomal nystatin in human, dog, and rat plasma.

M Ramaswamy1, T L Wallace, P A Cossum, K M Wasan.   

Abstract

The objective of this study was an interspecies comparison of free nystatin (NYS) and liposomal NYS (Nyotran) distribution in plasma. NYS and liposomal NYS at concentrations of 5, 10, and 20 microg of NYS/ml were incubated in human, dog, and rat plasma for 5, 60, and 180 min at 37 degrees C. Following these incubations, plasma samples were separated into their high-density lipoprotein (HDL), triglyceride-rich lipoprotein, low-density lipoprotein, and lipoprotein-deficient plasma (LPDP) fractions by density-gradient ultracentrifugation, and each fraction was assayed for NYS by high-pressure liquid chromatography. Total plasma and lipoprotein cholesterol, triglyceride, and protein concentrations in each human, dog, or rat plasma sample were determined by enzymatic assays. When NYS and liposomal NYS were incubated in human, dog, or rat plasma, the majority of the NYS was recovered in the LPDP fraction. For the 5- and 60-min incubation times for all plasmas measured, a significantly greater percentage of NYS was recovered in the lipoprotein fraction (primarily HDL) following the incubation of liposomal NYS than following the incubation of NYS. There was a significant correlation between the lipoprotein lipid and protein profiles in human, dog, and rat plasmas and the distribution of NYS and liposomal NYS in plasma. In particular, differences in the proportion of plasma lipoprotein cholesterol, triglyceride, and apolar lipids (cholesteryl ester and triglycerides) carried by HDL influenced the distribution of NYS and liposomal NYS within plasmas of different species. These findings suggest that the distribution of NYS among plasma lipoproteins of different species is defined by the proportion of lipid carried by HDL, and this is possibly an important consideration when evaluating the pharmacokinetics, toxicities, and activities of these compounds following administration to different animal species.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10348764      PMCID: PMC89290          DOI: 10.1128/AAC.43.6.1424

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  In vitro antiherpetic activity of water-soluble amphotericin B methyl ester.

Authors:  N M Stevens; C G Engle; P B Fisher; W Mechlinski; C P Schaffner
Journal:  Arch Virol       Date:  1975       Impact factor: 2.574

2.  Enhanced amphotericin B nephrotoxicity in intensive care patients with elevated levels of low-density lipoprotein cholesterol.

Authors:  K M Wasan; J S Conklin
Journal:  Clin Infect Dis       Date:  1997-01       Impact factor: 9.079

3.  Physical characteristics and lipoprotein distribution of liposomal nystatin in human plasma.

Authors:  K M Wasan; M Ramaswamy; S M Cassidy; M Kazemi; F W Strobel; R L Thies
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

4.  Inhibition of HIV replication by liposomal encapsulated amphotericin B.

Authors:  D R Pontani; D Sun; J W Brown; S I Shahied; O J Plescia; C P Schaffner; G Lopez-Berestein; P S Sarin
Journal:  Antiviral Res       Date:  1989-04       Impact factor: 5.970

5.  Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood.

Authors:  M Lemaire; J P Tillement
Journal:  J Pharm Pharmacol       Date:  1982-11       Impact factor: 3.765

6.  The antimalarial drug halofantrine is bound mainly to low and high density lipoproteins in human serum.

Authors:  B Cenni; J Meyer; R Brandt; B Betschart
Journal:  Br J Clin Pharmacol       Date:  1995-05       Impact factor: 4.335

7.  Evaluation of renal toxicity and antifungal activity of free and liposomal amphotericin B following a single intravenous dose to diabetic rats with systemic candidiasis.

Authors:  K M Wasan; J S Conklin
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

8.  Involvement of binding lipoproteins in the absorption and transport of alpha-tocopherol in the rat.

Authors:  O V Rajaram; P Fatterpaker; A Sreenivasan
Journal:  Biochem J       Date:  1974-06       Impact factor: 3.857

9.  Effects of elevation of serum cholesterol and administration of amphotericin B complexed to lipoproteins on amphotericin B-induced toxicity in rabbits.

Authors:  M H Koldin; G S Kobayashi; J Brajtburg; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

10.  Influence of diet on experimental toxicity of amphotericin B deoxycholate.

Authors:  P Chavanet; V Joly; D Rigaud; J Bolard; C Carbon; P Yeni
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

View more
  9 in total

Review 1.  Factors influencing the use and interpretation of animal models in the development of parenteral drug delivery systems.

Authors:  Marilyn N Martinez
Journal:  AAPS J       Date:  2011-10-05       Impact factor: 4.009

Review 2.  Comparison of Canine and Human Physiological Factors: Understanding Interspecies Differences that Impact Drug Pharmacokinetics.

Authors:  Marilyn N Martinez; Jonathan P Mochel; Sibylle Neuhoff; Devendra Pade
Journal:  AAPS J       Date:  2021-04-27       Impact factor: 4.009

Review 3.  Animal models for the atherosclerosis research: a review.

Authors:  Li Xiangdong; Liu Yuanwu; Zhang Hua; Ren Liming; Li Qiuyan; Li Ning
Journal:  Protein Cell       Date:  2011-04-06       Impact factor: 14.870

4.  Compartmental pharmacokinetics and tissue distribution of multilamellar liposomal nystatin in rabbits.

Authors:  A H Groll; D Mickiene; K Werner; R Petraitiene; V Petraitis; M Calendario; A Field-Ridley; J Crisp; S C Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

5.  Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers.

Authors:  Daniel P Rossignol; Kishor M Wasan; Eugene Choo; Edwin Yau; Nancy Wong; Jeffrey Rose; Jeffrey Moran; Melvyn Lynn
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

6.  Influence of plasma cholesterol and triglyceride concentrations and eritoran (E5564) micelle size on its plasma pharmacokinetics and ex vivo activity following single intravenous bolus dose into healthy female rabbits.

Authors:  Kishor M Wasan; Verica Risovic; Olena Sivak; Stephen D Lee; Douglas X Mason; Gregory R Chiklis; Jim McShane; Melvyn Lynn; Nancy Wong; Daniel P Rossignol
Journal:  Pharm Res       Date:  2007-09-12       Impact factor: 4.200

7.  Tetradecylthioacetic acid increases hepatic mitochondrial β-oxidation and alters fatty acid composition in a mouse model of chronic inflammation.

Authors:  Lena Burri; Bodil Bjørndal; Hege Wergedahl; Kjetil Berge; Pavol Bohov; Asbjørn Svardal; Rolf K Berge
Journal:  Lipids       Date:  2011-04-09       Impact factor: 1.880

8.  Identification of cyclopropaneoctanoic acid 2-hexyl in human adipose tissue and serum.

Authors:  Tomasz Sledzinski; Adriana Mika; Piotr Stepnowski; Monika Proczko-Markuszewska; Lukasz Kaska; Tomasz Stefaniak; Julian Swierczynski
Journal:  Lipids       Date:  2013-06-11       Impact factor: 1.880

9.  Plasma lipidomic analysis reveals strong similarities between lipid fingerprints in human, hamster and mouse compared to other animal species.

Authors:  Zied Kaabia; Julie Poirier; Michelle Moughaizel; Audrey Aguesse; Stéphanie Billon-Crossouard; Fanta Fall; Manon Durand; Elie Dagher; Michel Krempf; Mikaël Croyal
Journal:  Sci Rep       Date:  2018-10-26       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.